Based on ground-breaking research by Prof Steve Howdle, Critical Pharmaceuticals uses its supercritical fluid technologies to formulate drugs and drug candidates within biodegradable polymers for controlled release applications.
The first spin out company based on the School of Chemistry's research, Critical Pharmaceuticals was formed in 2002 and has since won numerous awards for innovation. Critical Pharmaceuticals has two proprietary technologies, which have entered clinical trials, are being developed as treatments for a number of medical conditions, including human growth hormone deficiency, schizophrenia and osteoporosis.
Qgenta is a spin-out company domiciled in Colorado, USA which has resulted from successful collaborative research between the Universities of Nottingham and the University of Colorado. A series of novel compounds developed by Prof. Chris Moody in the School of Chemistry at Nottingham and Prof David Ross and Dr David Siegel at Colorado have shown potential as the basis of future therapies for the treatment of solid tumours and in particular pancreatic cancers. Qgenta will provide a focus for rapid development and testing of these compounds and take them forward commercially.
School of ChemistryUniversity Park
Nottingham, NG7 2RD
telephone: +44 (0) 115 74 86268
Connect with the University of Nottingham through social media and our blogs.
Campus maps | More contact information | Jobs
Browser does not support script.